News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Genentech, Inc. (Jobs) Stock Down After Avastin Fails, Sales Stall
March 23, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
March 23 (Bloomberg) -- Shares of Genentech Inc., the world's second-biggest biotechnology company, fell the most in two years after first-quarter sales stalled and researchers halted a study of the cancer drug Avastin.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Cancer
AACR 2025 Tracker: GSK, Boehringer Ingelheim and Merck Kick Off Meeting With New Data
April 28, 2025
·
3 min read
·
BioSpace Editorial Staff
Cancer
Perioperative Keytruda Cuts Risk of Negative Events by Over 25% in Head and Neck Cancer
April 28, 2025
·
1 min read
·
Tristan Manalac
Cancer
Summit, Akeso’s Keytruda Challenger Wins Chinese OK as US Approval Questions Linger
April 28, 2025
·
3 min read
·
Tristan Manalac
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
April 25, 2025
·
2 min read
·
Tristan Manalac
